Weight-loss jabs can prevent heart patients from dying young

Weight loss jabs can reduce the risk of dying heart patients at a young age.

A Harvard study following 120,000 patients with heart failure shows that Mounjaro reduces the risk of death or hospital acceptance by 58 percent compared to standard diabetes therapy.

Meanwhile, Wegovy (Semaglidid) found that it has reduced the risk by 42 percent for six years.

An additional study by Wegovy producers has shown that both jabs can reduce the risk of heart attacks, paralysis and premature death among people with cardiovascular disease. Semagluid gave the most powerful protection.

Vice President of the European Cardiology Association “This shows that one of these two agents is a benefit to use to reduce the risk.

“We thought we wouldn’t find a treatment that will work well for a significant part of these patients.

“What is a good surprise is not through weight loss of these drugs, probably with other effects that go beyond weight loss.”